글로벌 심근병 시장 - 산업 동향 및 2028년까지의 예측

시장 분석 및 통찰력: 글로벌 심근병 시장

심근병 시장은 2021년에서 2028년의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 위에 언급된 연구 예측 기간 동안 7.90%의 CAGR로 성장하고 있다고 분석합니다. 노령 인구 증가와 심부전 유병률 증가가 시장 성장을 견인할 수 있습니다.

게다가 신흥 시장과 연구개발에 대한 막대한 투자도 시장 성장을 촉진합니다. 나아가 의료비 지출 증가와 파이프라인 치료법의 존재는 시장 성장의 기회로 작용합니다. 하지만 때로는 약물과 관련된 부작용, 효과적인 치료법 부족, 질병에 대한 인식 부족, 엄격한 규제 프레임워크 등이 글로벌 심근병 시장을 방해할 수 있습니다.

심근병증은 심장 근육과 관련이 있습니다. 심근병증은 모든 연령대의 사람에게 영향을 미치며 평생 질병으로 이어집니다. 심부전으로 이어질 수 있습니다. 비대성, 확장성 및 제한성 심근병증을 포함한 여러 유형의 심근병증이 있습니다. 심근병증과 관련된 일반적인 증상에는 호흡곤란, 복부 팽창, 다리, 발목 및 발의 붓기, 기침, 피로, 가슴 불편감, 현기증 등이 있습니다. 이미 장기간 고혈압, 만성적인 빠른 심박수, 대사 장애(갑상선 질환 또는 당뇨병), 육아종증 등이 있는 환자는 심근병증이 발생할 위험이 높습니다. 심근병증은 흉부 X선, 심초음파, 심장 카테터 검사, 심장 MRI, CT 스캔, 혈액 검사, 유전 및 캐러닝 검사를 사용하여 진단할 수 있습니다. 약물, 이식형 장치, 심장 펌프, 심장 전환기-제세동기 등을 포함하여 심장 근병증 치료에 적응되는 여러 가지 치료 옵션이 있습니다.

The prevalence of heart failure is increasing worldwide with reported 64.34 worldwide cases. This affected population is largely dependent upon the effective treatment options in order to lead a disease free life and hence expected to provide market with the lucrative growth. It is also estimated that cardiomyopathy market is growing with the CAGR of 7.90% in 2020.

This cardiomyopathy market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Cardiomyopathy Market Scope and Market Size

Cardiomyopathy market is segmented on the basis of type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the cardiomyopathy market is segmented into hypertrophic, dilated and restrictive cardiomyopathy.
• On the basis of diagnosis, the cardiomyopathy market is segmented into X- ray, echocardiogram, electrocardiogram, MRI, CT scan, blood tests among others.
• On the basis of treatment, the cardiomyopathy market is segmented into medication, implantable devices, heart pumps, cardioverter-defibrillators among others. Medication segment is further sub-segmented into ACE inhibitors, ARBs, beta-blockers among others. ACE inhibitors is further sub-segmented into benazepril, captopril, enalapril, fosinopril, Lisinopril, moexipril, perindopril, quinapril among others. ARBs is further sub-segmented into azilsartan, candesartan, losartan, valsartan, telmisartan, olmesartan among others. Beta- blockers sub-segmented into acebutolol, atenolol, metoprolol, nebivolol, nadolol, propranolol among others.
• On the basis of route of administration, the cardiomyopathy market is segmented into oral, parenteral and others.
• On the basis of end-users, the cardiomyopathy market is segmented into clinics, hospitals and others.
• On the basis of distribution channel, the cardiomyopathy market has also been segmented into direct tenders, retail sales, hospital pharmacy, retail pharmacy, online pharmacy and others. 

Cardiomyopathy Market Country Level Analysis

Cardiomyopathy market is analysed and market size information is provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the cardiomyopathy market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

On geographical estimation, North America accounts the largest market share due to the rising incidence of heart diseases and presence of refined healthcare facilities. Europe is also expected to grow exponentially due to technological advancements and rising initiatives by market players to expand the product distribution network. Asia-Pacific is expected to account for the largest market share due to the developing healthcare facilities and presence of large number of generic drug manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Cardiomyopathy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Cardiomyopathy Market Share Analysis

Cardiomyopathy market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to cardiomyopathy market.

심근병 시장에서 다루는 주요 기업으로는 Novartis AG, GlaxoSmithKline plc, Cipla Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zensun, Hikma Pharmaceuticals PLC, Endo International Inc, Zydus Cadila, Capricor Therapeutics, MyoKardia, Aastrom Biosciences, t2cure GmbH, Boston Scientific Corporation, Covance, Mylan NV, Pfizer, Inc., BG Medicine Inc., Biomerieux, Bio-Rad Laboratories 등이 있으며, 국내 및 글로벌 기업도 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.

SKU-54395